Loratadine-akrikhin tablets - instructions for use. Loratadine: what are these tablets for? Impact on the ability to drive vehicles and complex mechanisms

Loratadin-Akrikhin: instructions for use and reviews

Trade name of the drug:

Loratadin-Akrikhin

International nonproprietary name:

Dosage form:

Compound

Description.

Pharmacotherapeutic group:

Antiallergic agent - H1-histamine receptor blocker

ATX code:

Pharmacological properties

Indications for use:

Contraindications:

Carefully

Use during pregnancy and lactation

Directions for use and doses

Side effect

Overdose

Interaction with other drugs

special instructions

Release form:

Storage conditions

Best before date

Conditions for dispensing from pharmacies:

Manufacturer/Organization accepting consumer complaints:

Open Joint Stock Company "Chemical and Pharmaceutical Plant "AKRIKHIN" (JSC "AKRIKHIN"), Russia
142450, Moscow region, Noginsky district, Staraya Kupavna, st. Kirova, 29.

Allergy is the most unpleasant disease that can poison the quality of life. Itching, watery eyes, sneezing and other symptoms during illness terribly irritate a person, making him nervous. To combat this disease, many medications have been developed, among which Loratadine Akrikhin is enviably popular.

general information

Loratadine is an antiallergic drug that blocks histamine H1 receptors. It is included in the list of vital and important medications.

Its use was approved by the Food and Drug Administration (FDA) back in 1993.

Release form, composition, packaging

Loratadine is available in 2 forms - syrup and tablets.

The syrup is a yellow liquid with a slight fruity odor. It contains loratadine and additional components - ethanol, citric acid, propylene glycol, dye, benzoic acid, orange flavor, sucrose.

Pour the liquid into dark 100 ml bottles. In a cardboard package, along with the bottle, a measuring spoon or cup is supplied.

Tablets are usually produced white, flat, cylindrical in shape with a score. Composition: loratadine as the main active ingredient and auxiliary components (lactose, starch, calcium stearate). In a cardboard package there are 1 or 3 blisters containing 7 or 10 tablets.

Pharmacology

Loratadine blocks H1 histamine receptors for a long time. Prevents the release of histamine and organic compounds of the group of highly active lipid substances from mast cells (mast cells).

The medicine stops the development of allergies and softens the symptoms of the disease. It also eliminates itching, minimizes the thinness of capillaries, prevents excess fluid accumulation in tissues, and eliminates involuntary muscle contractions.

The antiallergic effect is observed half an hour after using the drug and reaches its maximum after 8-12 hours. The therapeutic effect lasts throughout the day.

The medication does not penetrate the blood-brain barrier, which prevents the body from becoming accustomed to the drug, and does not affect the central nervous system.

Difference from Larotadine

Since the drug in question and Loratadine have the same active ingredient, they have no differences in use.

The only distinguishing feature is the cost of the medicine, which depends on the manufacturer.

Pharmacokinetics

The drug is absorbed quite quickly into the gastrointestinal tract. However, it is worth remembering that eating food can slow down absorption by 60 minutes.

Binds to plasma proteins by 97%. Loratadine is excreted through the kidneys and bile.

Mechanism of action

Loratadine Akrikhin is an antihistamine. It creates obstacles to allergy symptoms for a day. It blocks the necessary receptors and inhibits the release of leukotriene C4.

The medicine removes inflammation, eliminates vasospasm, prevents or completely eliminates tissue swelling.

Indications

Loratadine is used for a number of phenomena. Among them:

• allergic rhinitis (seasonal or year-round);
• hives (rash);
• Quincke's edema;
• dermatosis accompanied by itching;
• , medicines;
• false allergic reaction provoked by the release of histamine;
• Elimination of itching in psoriasis, chicken pox.

Contraindications

The use of the medication is prohibited if several aspects are present. For example:

• breastfeeding period;
• children under two years of age;
• individual intolerance to the active agent or auxiliary components.

The presence of liver failure and pregnancy requires careful use of the medication.

Instructions for use

The medicine is intended for internal use.

Adults and children weighing more than 30 kg take 1 tablet or 2 scoops of syrup 30 minutes before meals, 1 time per 24 hours.

Children aged 2-12 years weighing less than 30 kg require the use of 1 scoop of liquid once a day.

In case of liver and kidney failure, the dose of the drug should not exceed 10 mg every 2 days or 5 mg every day.

However, before you start taking the medicine, you should definitely consult your doctor.

Overdose

If the drug is taken uncontrolled, an overdose may occur. It manifests itself as headache, rapid heartbeat, and drowsiness.

If such a phenomenon occurs, you need to rinse your stomach and take activated charcoal.

Side effects

Adverse effects may occur when using Loratadine. These include:

• skin rashes;
• dizziness and pain;
• anaphylaxis;
• drowsiness, feeling tired;
• nervous overexcitation;
• increased heart rate;
• nausea, inflammatory processes in the gastric mucosa;
• deterioration of liver function.

Side effects are usually very rare. The most common phenomenon is the craving for sleep.

Pregnancy and lactation

It is not yet known whether Loratadine is safe during pregnancy. Based on this, it is clear that its use during pregnancy is undesirable.

However, it is better to discuss the possibility of taking the medication with a competent specialist.

During breastfeeding, it is better to avoid treatment with this drug. It has the ability to pass into mother's milk.

Drug interactions

Drugs such as Erythromycin, Ketoconazole, Cemitidine increase the concentration of Loratadine in the blood. However, the clinical picture does not change and does not distort the electrocardiogram data.

Barbiturates, antidepressants, Rifampucin, on the contrary, reduce the productivity of Loratadine.

The medication does not increase the effect of alcoholic beverages on the central nervous system. But you should still be careful when using them together.

special instructions

The medication should be taken carefully by people driving vehicles and other mechanisms that require fast psychomotor skills and increased concentration.

Active substance

Loratadine

Release form, composition and packaging

◊ Pills white or almost white, flat-cylindrical, chamfered.

Excipients: lactose monohydrate - 110 mg, microcrystalline cellulose - 75 mg, calcium stearate - 2 mg, sodium carboxymethyl starch - 3 mg.

7 pcs. - contour cellular packaging (1) - cardboard packs.
7 pcs. - contour cell packaging (3) - cardboard packs.
10 pieces. - contour cellular packaging (1) - cardboard packs.
10 pieces. - contour cell packaging (3) - cardboard packs.

◊ Syrup in the form of a clear liquid from light yellow to yellow, with a faint fruity odor.

Excipients: sucrose - 35 g, propylene glycol - 20 g, benzoic acid - 0.1 g, citric acid - 0.3 g, ethanol (rectified) - 1.58 g, tropeolin O dye - 0.001 g, orange flavor - 0.08 g, purified water - up to 100 ml.

100 ml - dark glass bottles (1) complete with a measuring spoon - cardboard packs.

pharmachologic effect

Long-acting histamine H1 receptor blocker. Has anti-allergic, anti-exudative effects. Prevents the development and facilitates the course of allergic reactions.

Suppresses the release of histamine and leukotriene C4 from mast cells. Reduces capillary permeability, prevents the development of tissue edema, relieves spasms of smooth muscles.

Does not affect the central nervous system (because it does not penetrate the BBB) and is not addictive.

The antiallergic effect develops after 30 minutes, reaches a maximum after 8-12 hours and lasts 24 hours.

Pharmacokinetics

Suction and distribution

They are quickly and completely absorbed from the gastrointestinal tract. The time to reach Cmax in the blood after taking the drug is 1.3-2.5 hours; Eating slows down the time to reach Cmax by 1 hour.

Plasma protein binding - 97%. Css of loratadine and metabolite in plasma are achieved on the 5th day of administration. Does not penetrate the BBB.

Metabolism and excretion

Metabolized in the liver to form the active metabolite descarboethoxyloratadine with the participation of CYP3A4 isoenzymes and, to a lesser extent, CYP2D6.

Excreted by the kidneys and bile. T 1/2 of loratadine - 3-20 hours (average 8.4 hours), active metabolite - 8.8-92 hours (average 28 hours).

Pharmacokinetics in special groups of patients

C max of the drug in blood plasma in elderly people increases by 50%. T1/2 of loratadine and the active metabolite in elderly patients, respectively, is 6.7-37 hours (on average 18.2 hours) and 11-38 hours (17.5 hours).

With alcoholic liver damage, C max and T 1/2 increase in proportion to the severity of the disease.

In patients with chronic renal failure and during hemodialysis, the pharmacokinetics remain virtually unchanged.

Indications

• seasonal and year-round rhinitis (including hay fever);
• allergic conjunctivitis;
• urticaria (including chronic idiopathic);
• Quincke's edema;
• pseudo-allergic reactions caused by the release of histamine;
• itchy dermatoses;
• allergic reaction to insect bites.

Contraindications

• lactation period;
• children weighing less than 30 kg (for tablets);
• children under 2 years of age (for syrup);
• lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome (for tablets);
• hypersensitivity to any of the components of the drug.

WITH caution The drug should be prescribed for liver failure and pregnancy.

Dosage

The drug is taken orally.

Adults and Children weighing more than 30 kg Prescribe 10 mg (1 tablet or 2 measuring spoons of syrup) 1 time/day.

Children aged 2 to 12 years weighing less than 30 kg prescribed 5 mg (1 scoop of syrup) 1 time/day.

At renal failure The initial dose is 10 mg every other day.

At liver failure The initial dose of the drug is 5 mg/day or 10 mg every other day.

Side effects

Adverse events occurred at approximately the same frequency as with placebo.

In adults: headache, increased fatigue, dry mouth, drowsiness, nausea, gastritis, allergic reactions (rash), anaphylaxis, alopecia, liver dysfunction, tachycardia.

In children: headache, increased nervous excitability, sedation.

Overdose

Symptoms: drowsiness, tachycardia, headache.

Treatment: gastric lavage, taking activated carbon. Not excreted by hemodialysis.

Drug interactions

CYP3A4 inhibitors (including ketoconazole), CYP3A4 and CYP2D6 inhibitors (cimetidine and others), when used together with loratadine, increase the concentration of loratadine in the blood plasma without causing clinical manifestations and without affecting ECG data.

Inducers of microsomal oxidation (phenytoin, barbiturates, phenylbutazone, tricyclic antidepressants) reduce the effectiveness of loratadine.

Loratadine does not enhance the effect of ethanol on the central nervous system.

special instructions

Impact on the ability to drive vehicles and operate machinery

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

◊ Syrup in the form of a clear liquid from light yellow to yellow, with a faint fruity odor.

Sucrose - 35 g, propylene glycol - 20 g, benzoic acid - 0.1 g, citric acid - 0.3 g, ethanol (rectified ethyl alcohol) - 1.58 g, tropeolin O dye - 0.001 g, orange flavor - 0.08 g, purified water - up to 100 ml.

100 ml - dark glass bottles (1) complete with a measuring spoon - cardboard packs.

pharmachologic effect

Long-acting histamine H1 receptor blocker. It has antiallergic, antipruritic, antiexudative effects. Prevents the development and facilitates the course of allergic reactions.

Suppresses the release of histamine and leukotriene C4 from mast cells. Reduces capillary permeability, prevents the development of tissue edema, relieves spasms of smooth muscles.

Does not affect the central nervous system (because it does not penetrate the BBB) and is not addictive.

The antiallergic effect develops after 30 minutes, reaches a maximum after 8-12 hours and lasts 24 hours.

Pharmacokinetics

Suction and distribution

They are quickly and completely absorbed from the gastrointestinal tract. The time to reach Cmax in blood plasma after taking the drug is 1.3-2.5 hours; Eating slows down the time to reach Cmax by 1 hour.

Plasma protein binding - 97%. Css of loratadine and metabolite in plasma are achieved on the 5th day of administration. Does not penetrate the BBB.

Metabolism and excretion

Metabolized in the liver to form the active metabolite descarboethoxyloratadine with the participation of CYP3A4 isoenzymes and, to a lesser extent, CYP2D6.

Excreted by the kidneys and bile. T 1/2 of loratadine - 3-20 hours (average 8.4 hours), active metabolite - 8.8-92 hours (average 28 hours).

Pharmacokinetics in special groups of patients

C max of the drug in blood plasma in elderly people increases by 50%. T1/2 of loratadine and the active metabolite in elderly patients, respectively, is 6.7-37 hours (on average 18.2 hours) and 11-38 hours (17.5 hours).

With alcoholic liver damage, C max and T 1/2 increase in proportion to the severity of the disease.

In patients with chronic renal failure and during hemodialysis, the pharmacokinetics remain virtually unchanged.

Directions for use and doses

The drug is taken orally.

Adults and children weighing more than 30 kg Prescribe 10 mg (1 tablet or 2 measuring spoons of syrup) 1 time/day.

Children aged 2 to 12 years weighing less than 30 kg prescribed 5 mg (1 scoop of syrup) 1 time/day.

At renal failure The initial dose is 10 mg every other day.

At liver failure The initial dose of the drug is 5 mg/day or 10 mg every other day.

Overdose

Symptoms: drowsiness, tachycardia, headache.

Treatment: gastric lavage, taking activated carbon. Not excreted by hemodialysis.

Interaction with other l/s

CYP3A4 inhibitors (including erythromycin, ketoconazole), CYP3A4 and CYP2D6 inhibitors (cimetidine and others), when used together with loratadine, increase the concentration of loratadine in the blood plasma without causing clinical manifestations and without affecting ECG data.

Inducers of microsomal oxidation (phenytoin, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) reduce the effectiveness of loratadine.

Loratadine does not enhance the effect of ethanol on the central nervous system.

During pregnancy and breastfeeding

The use of the drug during pregnancy is possible only in cases where the expected benefit to the mother outweighs the potential risk to the fetus.

During treatment, breastfeeding should be stopped (excreted in breast milk).

Side effects

Adverse events occurred at approximately the same frequency as with placebo.

In adults: headache, increased fatigue, dry mouth, drowsiness, nausea, gastritis, allergic reactions (rash), anaphylaxis, alopecia, liver dysfunction, tachycardia.

In children: headache, increased nervous excitability, sedation.

Storage conditions and periods

The drug in tablet form should be stored in a dry place, out of reach of children, at a temperature not exceeding 25°C. Shelf life – 5 years.

The drug in syrup form should be stored in a dry place, out of reach of children, at a temperature of 12° to 15°C. Shelf life - 4 years.

Indications

— seasonal and year-round rhinitis (including hay fever);

- allergic conjunctivitis;

- urticaria (including chronic idiopathic);

- Quincke's edema;

- pseudo-allergic reactions caused by the release of histamine;

- itchy dermatoses;

- allergic reaction to insect bites.

Contraindications

- lactation period;

- children weighing less than 30 kg (for tablets);

- children under 2 years of age (for syrup);

- lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome (for tablets);

- hypersensitivity to any of the components of the drug.

WITH caution The drug should be prescribed for liver failure and pregnancy.

special instructions

Impact on the ability to drive vehicles and operate machinery

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.